Submission of Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novelix Pharmaceuticals has submitted a routine compliance certificate from its Registrar and Share Transfer Agent, Venture Capital and Corporate Investments Private Limited, for the quarter ended September 30, 2025. The certificate confirms that physical share certificates received for dematerialisation were properly mutilated and cancelled, and the names of NSDL and CDSL were updated as the registered owners within the SEBI-mandated 15-day window. The filing was signed by Whole-time Director Venkateshwarlu Pulluru and submitted to BSE under Scrip Code 536565.
This is a standard procedural compliance filing with no material impact on the company's financials, operations, or stock price. It simply confirms the company's adherence to SEBI depository regulations regarding share transfer records.